Stacks
Interaction Unknown
The 2026 Aljabri review (Saudi Medical Journal / PMC13227446) synthesises trial evidence across five clinical domains: type 2 diabetes glycaemic control, obesity weight management, cardiovascular risk reduction, renal protection, and emerging indications including MASH. Each domain carries a distinct evidence tier, interaction profile, and practical deployment constraint for protocol designers.
October 23, 2026
·
10 min read
Stacks
Interaction Unknown
The 2026 phase 3 dataset for the cagrilintide plus semaglutide combination spans REDEFINE 1, REDEFINE 2, and the REIMAGINE 1 through 3 program. These trials establish five trackable signal categories: body-weight reduction versus each monotherapy arm, glycaemic control, gastrointestinal adverse-event incidence, treatment-discontinuation rates, and cardiometabolic surrogate markers. Each category has a defined comparator arm and a measurable delta.
October 22, 2026
·
9 min read
Stacks
Interaction Unknown
Yes, with a critical species caveat. The September 2026 Nature Metabolism study (PMID 42744908) used pair-feeding and weight-matching controls in diet-induced obese male rats to show that cagrilintide plus retatrutide improves cholesterol, triglycerides, and insulin levels beyond what caloric restriction alone explains. No human co-administration trial exists; the interaction class upgrades to Co-Administration Data (Preclinical) but not to human evidence.
October 19, 2026
·
9 min read
Stacks
Interaction Unknown
A personal protocol running retatrutide or tirzepatide in 2026 must treat compound identity as an unresolved variable until third-party analytical testing confirms it. An August 2026 ABC Australia investigation and the Murugadoss et al. preprint of 652 gray-market retatrutide users document label substitutions, undeclared semaglutide, and concentration variances exceeding 2x stated dose. Identity uncertainty is a structural protocol constraint.
October 15, 2026
·
9 min read
Stacks
Interaction Unknown
A stack tracker for the tirzepatide plus eloralintide combination must capture fields across five categories: per-compound pharmacokinetic exposure, dual-pathway satiety outcome markers, GI tolerability signals, dose-arm interaction metadata, and evidence-tier flags. The EloraTZP Phase 2b readout (EASD 2026) provides the first controlled co-administration reference dataset but leaves lean-mass, cardiovascular, and long-term maintenance fields as evidence voids.
October 13, 2026
·
9 min read
Stacks
Interaction Unknown
The EASD 2026 Phase 2b readout for EloraTZP shows that adding eloralintide to tirzepatide produced up to 23 percent body-weight reduction at 48 weeks versus 15 percent for tirzepatide 15 mg alone. Adverse-event discontinuation reached 27 percent in the highest-dose arm versus 3 percent for tirzepatide monotherapy. Whether the efficacy increment justifies the tolerability burden is a dose-arm-specific calculation.
October 8, 2026
·
9 min read